Cellectar Biosciences, Inc. (CLRB)
Largest Insider Buys in Sector
CLRB Stock Price History Chart
CLRB Stock Performance
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company …
Insider Activity of Cellectar Biosciences, Inc.
Over the last 12 months, insiders at Cellectar Biosciences, Inc. have bought $0 and sold $0 worth of Cellectar Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Cellectar Biosciences, Inc. have bought $139,443 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $26,000 was made by Swirsky Douglas J (director) on 2021‑09‑14.
List of Insider Buy and Sell Transactions, Cellectar Biosciences, Inc.
| 2021-09-14 | director | 25,000 0.0418% | $1.04 | $26,000 | -43.80% | |||
| 2021-09-03 | director | 19,417 0.0328% | $1.04 | $20,244 | -42.72% | |||
| 2021-03-04 | President and CEO | 5,100 0.0103% | $1.70 | $8,659 | -43.68% | |||
| 2020-12-28 | Chief Business Officer | 29,630 0.0975% | $1.35 | $40,001 | -41.79% | |||
| 2020-12-28 | President and CEO | 37,037 0.1219% | $1.35 | $50,000 | -41.79% | |||
| 2020-12-28 | Chief Financial Officer | 7,407 0.0244% | $1.35 | $9,999 | -41.79% | |||
| 2020-06-05 | Chief Business Officer | 65,218 0.4749% | $1.15 | $74,675 | +26.32% | |||
| 2020-06-05 | President and CEO | 21,740 0.1583% | $1.15 | $24,892 | +26.32% | |||
| 2020-06-05 | Chief Financial Officer | 4,348 0.0317% | $1.15 | $4,978 | +26.32% | |||
| 2020-06-04 | director | 18,000 0.1236% | $1.08 | $19,438 | +25.88% | |||
| 2019-02-28 | Chief Business Officer | 100 0.0021% | $2.00 | $200 | +6.90% | |||
| 2018-11-30 | President and CEO | 1,000 0.0345% | $2.28 | $2,282 | -4.93% | |||
| 2018-11-29 | Sale | director | 992 0.0329% | $2.21 | $2,192 | -5.78% | ||
| 2018-08-16 | Chief Business Officer | 500 0.0149% | $2.71 | $1,355 | -22.38% | |||
| 2018-03-13 | Sale | Chief Business Officer | 13,000 0.0783% | $1.18 | $15,397 | -76.50% | ||
| 2018-03-12 | Sale | President and CEO | 34,000 0.2018% | $1.20 | $40,705 | -77.08% | ||
| 2017-11-14 | Sale | director | 5,214 0.0315% | $1.49 | $7,791 | -27.89% | ||
| 2016-11-29 | director | 333,333 2.668% | $1.49 | $496,666 | +6.45% | |||
| 2016-10-31 | Sale | 21,000 0.1919% | $2.03 | $42,609 | -9.19% | |||
| 2016-04-21 | 7,516 0.1746% | $1.90 | $14,280 | +21.69% |
Insider Historical Profitability
| MARXE AUSTIN W & GREENHOUSE DAVID M | 10 percent owner | 1142368 2.816% | $2.06 | 4 | 0 | |
| NEIS JOHN | director | 626103 1.5434% | $2.06 | 3 | 1 | +9.32% |
| Hertzberg Richard | 280000 0.6902% | $2.06 | 12 | 1 | <0.0001% | |
| BERNS PAUL L | director | 117371 0.2893% | $2.06 | 1 | 0 | +12.2% |
| Longcor Jarrod | Chief Business Officer | 102148 0.2518% | $2.06 | 4 | 1 | <0.0001% |
Institutional Investor Ownership
| Aigh Capital Management Llc | $11.16M | 7.82 | 2.8M | +46.45% | +$3.54M | 6.38 | |
| Nantahala Capital Management Llc | $7.46M | 5.23 | 1.87M | +38.7% | +$2.08M | 0.35 | |
| The Vanguard Group | $4.74M | 3.32 | 1.19M | +146.66% | +$2.82M | <0.0001 | |
| Barclays | $1.35M | 0.94 | 338,198 | New | +$1.35M | <0.01 | |
| Geode Capital Management | $1.26M | 0.88 | 316,084 | +358.96% | +$983,984.21 | <0.0001 |